{
  "pmcid": "12222409",
  "sha256": "e18b809daee65bbd4f8c9ee5a6a2c5165fae06a7fbff843a21deb2b9beb91fad",
  "timestamp_utc": "2025-11-09T22:19:05.493511+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.262360248447205,
    "reading_ease": 36.40869565217395,
    "word_count": 230
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial Comparing Portal Vein Embolization Techniques"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients eligible for major hepatectomy and requiring FLR optimization"
      },
      "Intervention": {
        "score": 2,
        "evidence": "PVE using either NBCA with iodized oil or PVA particles with coils"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare the efficacy of different embolic materials in portal vein embolization"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the degree of FLR hypertrophy at 28 days post-PVE"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applicable due to the nature of the intervention"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 100 patients were randomised, with 50 in each group"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 48 patients in the NBCA group and 47 in the PVA group using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The NBCA group showed significantly greater FLR hypertrophy (57% vs. 37%, p < 0.01)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 2/48 (4%) of the NBCA group and 3/47 (6%) of the PVA group"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institute of Health"
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}